AI assistant
Sending…
CRESCENT BIOPHARMA, INC. — Director's Dealing 2016
Jul 1, 2016
33678_dirs_2016-07-01_0431f81b-ec12-4bb7-9345-d3df3b098fc5.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: GLYCOMIMETICS INC (GLYC)
CIK: 0001253689
Period of Report: 2016-06-29
Reporting Person: Baldwin John J. (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2016-06-29 | Common Stock | M | 605 | $1.12 | Acquired | 1210 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2016-06-29 | Stock Option (right to buy) | $1.12 | M | 605 | Disposed | 2016-09-20 | Common Stock (605) | Direct |
Footnotes
F1: One-fourth of the shares underlying this option vested on September 20, 2007, and the remaining shares vested in 36 equal monthly installments thereafter.
More from CRESCENT BIOPHARMA, INC.
Declaration of Voting Results & Voting Rights Announcements
2026
Jun 3
Earnings Release
2026
Feb 26
Annual Report
2026
Feb 26
Major Shareholding Notification
2026
Feb 5
Capital/Financing Update
2026
Jan 15
Capital/Financing Update
2026
Jan 7
Director's Dealing
2025
Dec 17
Director's Dealing
2025
Dec 17
Director's Dealing
2025
Dec 17
Director's Dealing
2025
Dec 17